vs
Apple Hospitality REIT, Inc.（APLE）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Apple Hospitality REIT, Inc.的季度营收约是Bio-Techne的1.1倍（$337.7M vs $311.4M），Bio-Techne净利率更高（16.4% vs 8.2%，领先8.2%），Apple Hospitality REIT, Inc.同比增速更快（3.1% vs -1.5%），过去两年Bio-Techne的营收复合增速更高（1.3% vs -6.9%）
莱曼 hospitality properties是一家深耕酒店、度假村、娱乐及媒体领域的企业，得名于旗下核心资产——位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾作为爱德华·盖洛德旗下俄克拉荷马出版公司子公司的时期，1983年收购WSM公司后，拿下大奥普里等知名IP，奠定了如今的业务发展基础。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
APLE vs TECH — 直观对比
营收规模更大
APLE
是对方的1.1倍
$311.4M
营收增速更快
APLE
高出4.6%
-1.5%
净利率更高
TECH
高出8.2%
8.2%
两年增速更快
TECH
近两年复合增速
-6.9%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $337.7M | $311.4M |
| 净利润 | $27.7M | $51.0M |
| 毛利率 | — | 66.9% |
| 营业利润率 | 14.2% | 24.2% |
| 净利率 | 8.2% | 16.4% |
| 营收同比 | 3.1% | -1.5% |
| 净利润同比 | 12.7% | 126.0% |
| 每股收益（稀释后） | $0.12 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLETECH
| Q1 26 | $337.7M | $311.4M | ||
| Q4 25 | $326.4M | $295.9M | ||
| Q3 25 | $373.9M | — | ||
| Q2 25 | $384.4M | $317.0M | ||
| Q1 25 | $327.7M | $316.2M | ||
| Q4 24 | $333.0M | $297.0M | ||
| Q3 24 | $378.8M | $289.5M | ||
| Q2 24 | $390.1M | $306.1M |
净利润APLETECH
| Q1 26 | $27.7M | $51.0M | ||
| Q4 25 | $29.6M | $38.0M | ||
| Q3 25 | $50.9M | — | ||
| Q2 25 | $63.6M | $-17.7M | ||
| Q1 25 | $31.2M | $22.6M | ||
| Q4 24 | $29.8M | $34.9M | ||
| Q3 24 | $56.3M | $33.6M | ||
| Q2 24 | $73.9M | $40.6M |
毛利率APLETECH
| Q1 26 | — | 66.9% | ||
| Q4 25 | 37.2% | 64.6% | ||
| Q3 25 | 40.6% | — | ||
| Q2 25 | 42.6% | 62.7% | ||
| Q1 25 | 39.0% | 67.9% | ||
| Q4 24 | 38.6% | 65.3% | ||
| Q3 24 | 41.9% | 63.2% | ||
| Q2 24 | 44.6% | 66.4% |
营业利润率APLETECH
| Q1 26 | 14.2% | 24.2% | ||
| Q4 25 | 15.2% | 18.4% | ||
| Q3 25 | 19.4% | — | ||
| Q2 25 | 22.1% | -7.5% | ||
| Q1 25 | 15.5% | 12.2% | ||
| Q4 24 | 15.0% | 16.0% | ||
| Q3 24 | 20.5% | 13.8% | ||
| Q2 24 | 24.0% | 15.0% |
净利率APLETECH
| Q1 26 | 8.2% | 16.4% | ||
| Q4 25 | 9.1% | 12.8% | ||
| Q3 25 | 13.6% | — | ||
| Q2 25 | 16.6% | -5.6% | ||
| Q1 25 | 9.5% | 7.1% | ||
| Q4 24 | 9.0% | 11.7% | ||
| Q3 24 | 14.9% | 11.6% | ||
| Q2 24 | 19.0% | 13.3% |
每股收益（稀释后）APLETECH
| Q1 26 | $0.12 | $0.32 | ||
| Q4 25 | $0.13 | $0.24 | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.27 | $-0.11 | ||
| Q1 25 | $0.13 | $0.14 | ||
| Q4 24 | $0.13 | $0.22 | ||
| Q3 24 | $0.23 | $0.21 | ||
| Q2 24 | $0.31 | $0.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.8M | $209.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.1B | $2.1B |
| 总资产 | $4.9B | $2.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLETECH
| Q1 26 | $7.8M | $209.8M | ||
| Q4 25 | $8.5M | $172.9M | ||
| Q3 25 | $50.3M | — | ||
| Q2 25 | $7.9M | $162.2M | ||
| Q1 25 | $14.9M | $140.7M | ||
| Q4 24 | $10.3M | $177.5M | ||
| Q3 24 | $6.1M | $187.5M | ||
| Q2 24 | $7.2M | $152.9M |
总债务APLETECH
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $260.0M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $346.0M | ||
| Q1 25 | $1.5B | $330.0M | ||
| Q4 24 | $1.5B | $300.0M | ||
| Q3 24 | $1.5B | $300.0M | ||
| Q2 24 | $1.5B | $319.0M |
股东权益APLETECH
| Q1 26 | $3.1B | $2.1B | ||
| Q4 25 | $3.1B | $2.0B | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.2B | $1.9B | ||
| Q1 25 | $3.2B | $2.0B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $3.3B | $2.1B | ||
| Q2 24 | $3.3B | $2.1B |
总资产APLETECH
| Q1 26 | $4.9B | $2.6B | ||
| Q4 25 | $4.9B | $2.5B | ||
| Q3 25 | $4.9B | — | ||
| Q2 25 | $4.9B | $2.6B | ||
| Q1 25 | $4.9B | $2.6B | ||
| Q4 24 | $5.0B | $2.7B | ||
| Q3 24 | $5.0B | $2.7B | ||
| Q2 24 | $5.1B | $2.7B |
负债/权益比APLETECH
| Q1 26 | — | — | ||
| Q4 25 | 0.49× | 0.13× | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.48× | 0.18× | ||
| Q1 25 | 0.48× | 0.16× | ||
| Q4 24 | 0.45× | 0.14× | ||
| Q3 24 | 0.46× | 0.14× | ||
| Q2 24 | 0.46× | 0.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLE
| Comparable Hotels Total Revenue | $336.9M | 100% |
| RevPAR (Comparable Hotels) | $114.6K | 0% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
